| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | Elomotecan Basic information |
| Product Name: | Elomotecan | | Synonyms: | Elomotecan;(R)-EloMotecan;(5R)-9-Chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione;3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione,9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-,(5R)- | | CAS: | 220998-10-7 | | MF: | C29H32ClN3O4 | | MW: | 522.04 | | EINECS: | | | Product Categories: | | | Mol File: | 220998-10-7.mol |  |
| | Elomotecan Chemical Properties |
| Boiling point | 821.3±65.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | pka | 12.29±0.20(Predicted) |
| | Elomotecan Usage And Synthesis |
| Uses | Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II[1]. | | IC 50 | Topoisomerase I; Topoisomerase II | | References | [1] Trocóniz IF, et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(2):239-250. DOI:10.1007/s00280-012-1906-y |
| | Elomotecan Preparation Products And Raw materials |
|